Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).
Ontology highlight
ABSTRACT: Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals.
Oral administration of Placebo 7.5g/day t.i.d. after meals.
Primary outcome(s): Incidence of oral mucositis. grade>=2
Study Design: Parallel Randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2619737 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA